Published in Gene Therapy Weekly, March 30th, 2006
"TGF-beta is a potent immunosuppressant. High levels of TGF-beta produced by cancer cells have a negative inhibition effect on surrounding host immune cells and leads to evasion of the host immune surveillance and tumor progression.
"In the present study," wrote Q. Zhang and colleagues, Northwestern University, "we report a distinct ability of tumor reactive, TGF-beta-insensitive CD8+ T cells to infiltrate into established...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.